Advanced Delivery and Controlled Release Technology 

- The InnoBM’s unique drug delivery and controlled release technology can more precisely control the spatial and temporal distribution of drugs, so that the drugs can reach the lesion site more efficiently, and work there for a long time. This technology allows us to repurpose approved drugs for new indications or new administration routes. 

For example, BM201 is an extended-release microparticle formulation of TLR7/8 immune agonist that can be combined with radiotherapy / immunotherapy to sustainably activate tumor-specific immune responses. The Z-PEP platform is a drug delivery vehicle which can realize oral or eye drop delivery of antibody drugs, for treatment of inflammatory bowel diseases (IBD) or retinal fundus diseases, respectively.

Biomaterials for Modulation of Lesion Microenvironments 

- The InnoBM’s unique biomaterial technology can modulate the lesion microenvironment, thereby activating the immunosuppressive tumor microenvironment (positive regulation) or alleviating the inflammatory microenvironment (negative regulation). Based on this strategy, new generations of breakthrough therapies can be developed for tumor or inflammatory diseases. 

Examples: BM601 can significantly improve the efficacy of TACE therapy through continuous regulation of the tumor microenvironment. JN002 can achieve efficient and safe treatment for dry eye syndrome by continuously alleviating oxidative stress on the ocular surface.